EA023679B1 - АНТИ-EpCAM АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ - Google Patents
АНТИ-EpCAM АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ Download PDFInfo
- Publication number
- EA023679B1 EA023679B1 EA200970923A EA200970923A EA023679B1 EA 023679 B1 EA023679 B1 EA 023679B1 EA 200970923 A EA200970923 A EA 200970923A EA 200970923 A EA200970923 A EA 200970923A EA 023679 B1 EA023679 B1 EA 023679B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- ersam
- epcam
- fragment
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000000427 antigen Substances 0.000 claims abstract description 10
- 102000036639 antigens Human genes 0.000 claims abstract description 10
- 108091007433 antigens Proteins 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 57
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 43
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 25
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 11
- 210000004408 hybridoma Anatomy 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 229960002685 biotin Drugs 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 201000005296 lung carcinoma Diseases 0.000 claims description 4
- 238000011363 radioimmunotherapy Methods 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 108090001008 Avidin Proteins 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 2
- 201000001531 bladder carcinoma Diseases 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000010749 gastric carcinoma Diseases 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000002797 proteolythic effect Effects 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
- 238000012800 visualization Methods 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000010186 staining Methods 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 9
- 229960001776 edrecolomab Drugs 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 201000008808 Fibrosarcoma Diseases 0.000 description 5
- 101100261999 Rattus norvegicus Tpsab1 gene Proteins 0.000 description 5
- 101100129592 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcp7 gene Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 101100296683 Arabidopsis thaliana PCR11 gene Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 101000800463 Homo sapiens Transketolase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102220469221 S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B_E18A_mutation Human genes 0.000 description 1
- 241001246910 Saba Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000021158 homophilic cell adhesion Effects 0.000 description 1
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical group O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000005122 simple epithelium Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000901 systemic toxic effect Toxicity 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000013298 xenograft nude mouse model Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07105628 | 2007-04-04 | ||
| PCT/EP2008/053913 WO2008122551A2 (en) | 2007-04-04 | 2008-04-02 | Anti-epcam antibody and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200970923A1 EA200970923A1 (ru) | 2010-04-30 |
| EA023679B1 true EA023679B1 (ru) | 2016-06-30 |
Family
ID=38458122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200970923A EA023679B1 (ru) | 2007-04-04 | 2008-04-02 | АНТИ-EpCAM АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ |
Country Status (21)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2513747C (en) | 2003-01-24 | 2017-03-07 | University Of Utah | Methods of predicting mortality risk by determining telomere length |
| AU2009329987B2 (en) | 2008-12-22 | 2016-08-04 | University Of Utah Research Foundation | Monochrome multiplex quantitative PCR |
| GB0909904D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| CN110763842A (zh) | 2011-06-29 | 2020-02-07 | 中央研究院 | 使用表面涂层对生物物质的捕获、纯化和释放 |
| EP2819695B1 (en) * | 2012-03-02 | 2018-06-27 | Academia Sinica | ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF |
| US9494500B2 (en) | 2012-10-29 | 2016-11-15 | Academia Sinica | Collection and concentration system for biologic substance of interest and use thereof |
| JP6546158B2 (ja) | 2013-05-22 | 2019-07-17 | テロメア ダイアグノスティクス インコーポレイテッド | 短いテロメアの存在量の測定 |
| EP3126814B1 (en) | 2014-04-01 | 2019-06-12 | Academia Sinica | Methods and systems for cancer diagnosis and prognosis |
| EP2998026B1 (en) | 2014-08-26 | 2024-01-17 | Academia Sinica | Collector architecture layout design |
| CN107208145A (zh) | 2014-12-30 | 2017-09-26 | 端粒诊断公司 | 多重定量pcr |
| EP3328897A1 (en) * | 2015-07-31 | 2018-06-06 | Sutro Biopharma, Inc. | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES |
| US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
| WO2017173091A1 (en) * | 2016-03-30 | 2017-10-05 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination |
| US20190262397A1 (en) | 2016-07-26 | 2019-08-29 | Tessa Therapeutics Pte. Ltd. | Chimeric antigen receptor |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| AU2019402097A1 (en) | 2018-12-17 | 2021-06-10 | Revitope Limited | Twin immune cell engager |
| CN113597432B (zh) * | 2019-04-22 | 2023-05-02 | 江苏恒瑞医药股份有限公司 | 抗EpCAM抗体及其应用 |
| CN114026127B (zh) | 2019-06-11 | 2024-10-29 | 生物蛋白有限公司 | 条件活性抗epcam抗体、抗体片段、其免疫缀合物以及其用途 |
| CN110950959B (zh) * | 2020-02-25 | 2020-07-03 | 和铂医药(上海)有限责任公司 | 靶向EpCAM的抗体及其制备和应用 |
| CN112094350B (zh) * | 2020-06-01 | 2024-01-05 | 普众发现医药科技(上海)有限公司 | 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体 |
| WO2022037323A1 (zh) * | 2020-08-19 | 2022-02-24 | 上海易慕峰生物科技有限公司 | 人源化抗体、嵌合抗原受体、核酸、载体、细胞及应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005080428A2 (en) * | 2004-02-13 | 2005-09-01 | Micromet Ag | Anti-epcam immunoglobulins |
| US20060105389A1 (en) * | 2004-10-19 | 2006-05-18 | Kordyum Vitaliy A | Method for obtaining single chain antibodies to human interferon alpha2b |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| IT1245748B (it) | 1990-12-21 | 1994-10-14 | Mini Ricerca Scient Tecnolog | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
| US5578287A (en) * | 1992-06-09 | 1996-11-26 | Neorx Corporation | Three-step pretargeting methods using improved biotin-active agent |
| JP3427871B2 (ja) * | 1996-06-24 | 2003-07-22 | 戸田工業株式会社 | コバルト被着型針状磁性酸化鉄粒子粉末 |
| ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
-
2008
- 2008-04-02 PT PT08759374T patent/PT2142570E/pt unknown
- 2008-04-02 PL PL08759374T patent/PL2142570T3/pl unknown
- 2008-04-02 SI SI200830364T patent/SI2142570T1/sl unknown
- 2008-04-02 MX MX2009010444A patent/MX2009010444A/es active IP Right Grant
- 2008-04-02 EA EA200970923A patent/EA023679B1/ru not_active IP Right Cessation
- 2008-04-02 HR HR20110620T patent/HRP20110620T1/hr unknown
- 2008-04-02 EP EP08759374A patent/EP2142570B1/en active Active
- 2008-04-02 JP JP2010501503A patent/JP5631733B2/ja not_active Expired - Fee Related
- 2008-04-02 CN CN200880015767.4A patent/CN101970497B/zh not_active Expired - Fee Related
- 2008-04-02 RS RS20110388A patent/RS52040B/sr unknown
- 2008-04-02 WO PCT/EP2008/053913 patent/WO2008122551A2/en not_active Ceased
- 2008-04-02 US US12/594,559 patent/US8318911B2/en not_active Expired - Fee Related
- 2008-04-02 AU AU2008235566A patent/AU2008235566B2/en not_active Ceased
- 2008-04-02 KR KR1020097023099A patent/KR101683884B1/ko not_active Expired - Fee Related
- 2008-04-02 CA CA2682296A patent/CA2682296C/en not_active Expired - Fee Related
- 2008-04-02 AT AT08759374T patent/ATE512988T1/de active
- 2008-04-02 BR BRPI0810096A patent/BRPI0810096A8/pt not_active Application Discontinuation
- 2008-04-02 ES ES08759374T patent/ES2367675T3/es active Active
- 2008-04-02 DK DK08759374.5T patent/DK2142570T3/da active
-
2009
- 2009-09-24 IL IL201196A patent/IL201196A0/en active IP Right Grant
-
2011
- 2011-09-06 CY CY20111100854T patent/CY1111819T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005080428A2 (en) * | 2004-02-13 | 2005-09-01 | Micromet Ag | Anti-epcam immunoglobulins |
| US20060105389A1 (en) * | 2004-10-19 | 2006-05-18 | Kordyum Vitaliy A | Method for obtaining single chain antibodies to human interferon alpha2b |
Non-Patent Citations (4)
| Title |
|---|
| FRODIN JAN-ERIK ET AL: "MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma." HYBRIDOMA AND HYBRIDOMICS APR 2002, vol. 21, no. 2, April 2002 (2002-04), pages 99-101, XP002450070. ISSN: 1536-8599 the whole document * |
| NAUNDORF S ET AL: "In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment". INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 100, no. 1, 2002, pages 101-110, XP002253132. ISSN: 0020-7136 the whole document * |
| PRANG N ET AL: "Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines". BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 92, no. 2, 31 January 2005 (2005-01-31), pages 342-349, XP002437689 ISSN: 0007-0920 the whole document * |
| WENT P ET AL: "Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers." BRITISH JOURNAL OF CANCER 16 JAN 2006, vol. 94, no. 1, 16 January 2006 (2006-01-16), pages 128-135, XP002450071. ISSN: 0007-0920 the whole document * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100016237A (ko) | 2010-02-12 |
| RS52040B (sr) | 2012-04-30 |
| JP5631733B2 (ja) | 2014-11-26 |
| PL2142570T3 (pl) | 2011-11-30 |
| AU2008235566B2 (en) | 2013-06-06 |
| ES2367675T3 (es) | 2011-11-07 |
| PT2142570E (pt) | 2011-09-13 |
| WO2008122551A9 (en) | 2009-02-05 |
| KR101683884B1 (ko) | 2016-12-07 |
| IL201196A0 (en) | 2010-05-17 |
| EP2142570B1 (en) | 2011-06-15 |
| US8318911B2 (en) | 2012-11-27 |
| JP2010523096A (ja) | 2010-07-15 |
| AU2008235566A1 (en) | 2008-10-16 |
| CN101970497B (zh) | 2017-05-10 |
| EP2142570A2 (en) | 2010-01-13 |
| CA2682296A1 (en) | 2008-10-16 |
| MX2009010444A (es) | 2009-10-20 |
| BRPI0810096A8 (pt) | 2017-12-26 |
| CA2682296C (en) | 2017-02-28 |
| CN101970497A (zh) | 2011-02-09 |
| US20100092491A1 (en) | 2010-04-15 |
| SI2142570T1 (sl) | 2012-01-31 |
| CY1111819T1 (el) | 2015-10-07 |
| ATE512988T1 (de) | 2011-07-15 |
| EA200970923A1 (ru) | 2010-04-30 |
| WO2008122551A2 (en) | 2008-10-16 |
| BRPI0810096A2 (pt) | 2014-10-21 |
| HRP20110620T1 (hr) | 2011-09-30 |
| DK2142570T3 (da) | 2011-10-03 |
| WO2008122551A3 (en) | 2008-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA023679B1 (ru) | АНТИ-EpCAM АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ | |
| US12162950B2 (en) | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis | |
| EP3473649A1 (en) | Anti-cd47 monoclonal antibody and application thereof | |
| JP7712338B2 (ja) | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ | |
| EP4389766A1 (en) | Anti-igsf1 antibody and use thereof | |
| JP4826697B2 (ja) | 個別化抗ガン抗体 | |
| CN117510636B (zh) | Gprc5d抗体及其应用 | |
| US20240368259A1 (en) | Antibodies against lefty proteins | |
| HK40005045A (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| HK40055783B (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| HK40055783A (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| HK40000286B (en) | Gene products differentially expressed in tumors and their uses | |
| HK40000286A (en) | Gene products differentially expressed in tumors and their uses | |
| HK40005045B (zh) | 用於治疗ror1癌症并抑制转移的抗体和疫苗 | |
| JPWO1999040118A1 (ja) | ヒトｖｅｇｆ受容体ｋｄｒに対する抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): TJ |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TM RU |